Esophageal squamous cell carcinoma carries one of the grimmer prognoses in oncology, partly because its molecular drivers remain incompletely mapped. Identifying how the tumor microenvironment actively silences protective genes could reshape both diagnostic stratification and therapeutic targeting — and that is precisely what this mechanistic study begins to deliver.
Using single-cell RNA sequencing integrated with in vitro and in vivo models, investigators identified a specific subset of tumor-infiltrating macrophages marked by apolipoprotein C expression (APOC⁺). These macrophages communicate with esophageal tumor cells through the amphiregulin-EGFR (AREG-EGFR) axis, which sustains MAPK/ERK signaling and fosters an immunosuppressive niche. Against this backdrop, the dual-specificity phosphatase DUSP5 — an endogenous brake on ERK1/2 activity — is markedly downregulated in ESCC tissue. Restoring DUSP5 expression curbed cell proliferation, triggered senescence and apoptosis, and blunted migratory and invasive capacity. In xenograft mouse models, DUSP5 overexpression reduced both tumor growth and metastasis, while DUSP5 knockout in a carcinogen-induced model amplified tumor burden — effects reversed by ERK1/2 inhibition. The study's most conceptually significant contribution is the delineation of a self-reinforcing feedback loop: ERK1/2 activates the transcription factor ELK1, which in turn transcriptionally represses DUSP5, thus perpetuating ERK1/2 hyperactivation.
DUSP family phosphatases have been studied in colorectal, lung, and thyroid cancers, but their role in ESCC has been undercharacterized. This work positions DUSP5 as a bona fide tumor suppressor rather than a passive ERK regulator, and the feedback circuitry it describes has potential implications for resistance to EGFR-targeted therapies. Key limitations include the predominantly preclinical nature of the evidence and reliance on xenograft rather than syngeneic immune-competent models, which constrains conclusions about macrophage-tumor crosstalk in vivo. The prognostic gene signature derived from APOC⁺ macrophages merits prospective validation in large patient cohorts before clinical application. Overall, this represents a mechanistically detailed, incremental-to-meaningful advance in ESCC biology.